A large RSU vest can leave tax due when flat withholding misses total household income and the Massachusetts 4% millionaires surtax — check before Dec. 31. Keep reading to learn how to avoid tax surprises, and other problems that may coincide with an unexpected tax bill.

Schneider Electric is acquiring PTC for $205 per share in cash. Learn what happens to your PTC RSUs, PSUs, ESPP and owned shares, and how to plan ahead.

Your company was acquired and your equity paid out. Decide what the money is for first — then reserve for taxes, invest deliberately, and read your new grants.

Signing a partnership with big pharma can move your clinical-stage biotech's stock price. This is a planning trigger to consider what you own, and if it makes sense to sell some of your shares.

You just got the notice. Your company is running a tender offer — a program that lets employees sell some of their shares for cash while the company is still private — and there's a closing date. Now you're stuck on one question. How much should you sell? The instinct most people feel is to treat this as a simple yes-or-no bet on whether the company still has room to run. In reality, it’s much more nuanced than that.

Keeping your job after an acquisition can mean your equity vesting doesn't accelerate. Single- vs double-trigger vesting decides whether you're paid at close.

When a Phase 3 readout triples your biotech stock, separate the sell decision from execution. Also be sure to confirm your trading window status and tax lots first.

After an acquisition announcement, your plan documents—not the deal FAQ—determine whether unvested awards accelerate, convert, and trigger tax at close. Keep reading to learn how your stock payout is handled.

Once a PE-backed sale is announced, your stock option choices may vanish. Learn what to plan for — exercise, payouts, liquidation preferences — before the deal breaks.

Your pay didn't shrink when you made director or VP — it got lumpier. Salary still covers the bills, but half your compensation now lands in quarterly bursts of stock, each with its own tax bill and trading window. Here's how to set one framework that tells every vesting where to go, before the shares arrive.

When employer stock becomes the largest asset on your balance sheet, your retirement date quietly attaches to one company's stock price — and to whether that price shows up at the right level in the exact years you need to spend it. Keep reading to learn how to avoid that situation.

Facing a 90-day window to exercise your ISOs after leaving a private company? Understand IRS rules, potential AMT impact, and the liquidity challenges involved.

Clinical stage biotech employees holding employer stock face binary outcomes they can't control. Learn how to make deliberate decisions about your equity before an FDA decision is made for you.

Generate Biomedicines' lockup expires in August 2026. Here's what employees with appreciated equity should do before the trading window opens.

Most directors and VPs at Amazon, Google, and Microsoft didn't choose to make employer stock their largest asset. Here's what happens when tax aversion, a market decline, or a layoff forces the decision for you.

A VP promotion changes more than your title. Your equity just became the largest part of your compensation — and ignoring it is no longer a neutral decision. Here's what changes and what to do about it.

Selling your business is a financial and personal inflection point. Here's why the first year feels disorienting, and what to do before the emotions of the moment drive the wrong decisions.

Most executives don't decide to build a concentrated position in employer stock. They just never decide to sell. Every vest that passes without action is a decision — one that makes the next decision harder. Here's why RSU concentration compounds quietly, and why waiting for the "right time" to sell is the most expensive habit in executive compensation.

If your company is in M&A discussions, your equity deserves more attention than your org chart. By the time a deal is announced, the terms of your payout are largely set — and the window for tax planning has mostly closed. But that doesn't mean there's nothing left to do. Understanding exactly how your options and RSUs are treated in a transaction, and verifying that your payout is actually calculated correctly, can be the difference between capturing what you've earned and leaving significant money on the table.

The IPO is done. The celebration is over. Now comes the part that actually matters. The 180-day lockup period is not a rest period — it is the planning period. Here's what employees with stock options and RSUs need to understand about liquidity, valuation, and taxes before the lockup expires.